Reports
Sale
Exocrine Pancreatic Insufficiency Treatment Market Size: By Treatment: Pancreatic Enzyme Replacement Therapy (PERT), Nutritional Therapy (Dietary Supplements), Others; By Indication: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Others; By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Exocrine Pancreatic Insufficiency Treatment Market Size
The exocrine pancreatic insufficiency treatment market was valued at USD 4.22 billion in 2023, driven by the increasing cases of cystic fibrosis, which commonly develop EPI due to thickened secretions that obstruct the pancreatic ducts across the 8 major markets. The market is expected to grow at a CAGR of 8.27% during the forecast period of 2024-2032, with the values likely to reach USD 8.63 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Exocrine Pancreatic Insufficiency Treatment Market Outlook
- The incidence of chronic pancreatitis, a leading cause of EPI, is rising due to factors such as alcohol abuse, smoking, and obesity, which is driving the growth of the market. According to an article pu blished by National Institute of Health, the annual incidence of acute pancreatitis (AP) is estimated to be approximately 40/100,000 persons in the United States, resulting in over 130,000 new cases per year.
- Increasing incidence of pancreatic cancer, often associated with EPI due to tumor-induced obstruction of pancreatic ducts is expected to further fuel the market growth.
- The ongoing research into new therapeutic targets and formulations for exocrine pancreatic insufficiency treatment drives market expansion. Companies are leveraging technological advancements in biotechnology and drug delivery systems to enhance product offerings results into market expansion.
Exocrine Pancreatic Insufficiency Treatment Market Overview
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the inability of the pancreas to produce enough digestive enzymes to properly digest food. The treatment includes PERT, which involves taking pancreatic enzyme supplements with meals and snacks to replace the deficient enzymes. The enzyme supplements typically contain lipase, protease, and amylase to aid in the digestion of fats, proteins, and carbohydrates.
EPI is primarily caused by conditions that affect pancreatic function, such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and pancreatic surgery. The prevalence of these underlying conditions contributes to the growing demand for EPI treatment market.
The pharmaceutical companies are focusing on developing advanced formulations of pancreatic enzymes to improve stability, efficacy, and patient compliance. These innovations aim to optimize treatment outcomes and enhance patient satisfaction, which is expected to drive the market growth.
Exocrine Pancreatic Insufficiency Treatment Market Growth Drivers
Increasing Incidence and Prevalence of Underlying Conditions
Chronic pancreatitis is a significant cause of EPI, which is increasingly diagnosed due to rising cases linked to alcohol abuse, obesity, and other factors. This genetic condition affects pancreatic function, leading to EPI in a substantial number of patients. According to an article published by NCB I, chronic pancreatitis is the most common pancreatic disease associated with EPI.
Other conditions like pancreatic cancer and surgical interventions on the pancreas can impair its ability to produce digestive enzymes, necessitating EPI treatment. According to an article published by NCB I, pancreatic surgery alters digestive anatomy, the correct mixing of food, bile, and pancreatic enzymes and reduces the pancreatic volume. Different procedures are associated with different degrees of EPI. The growing number of individuals diagnosed with chronic pancreatitis directly expands the pool of patients at risk of developing EPI, thereby increasing the demand for its treatment market.
Technological Advancements in Treatment Options is Expected to Propel Exocrine Pancreatic Insufficiency Treatment Market Demand
The technological advancements in treatment options play a crucial role in driving the growth and development of the treatment market. The technological innovations enable the development of more effective formulations of pancreatic enzymes, including lipase, protease, and amylase. These formulations are designed to better mimic natural pancreatic enzyme activity, thereby improving digestion and nutrient absorption in patients with EPI. Pancreatic Enzyme Replacement Therapy (PERT) remains the mainstay of EPI treatment, with ongoing advancements in enzyme formulations, delivery systems, and dosing regimens to enhance efficacy and patient compliance.
The advancement in treatment includes other alternative therapies, exploration of adjunctive therapies, such as proton pump inhibitors (PPIs), dietary modifications, and nutritional supplements, provides additional treatment options tailored to patient needs. This innovation leads to increase in market demand.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Exocrine Pancreatic Insufficiency Treatment Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Advancements in Enzyme Replacement Therapy | There is ongoing research and development aimed at enhancing the efficacy, stability, and bioavailability of pancreatic enzyme replacement therapy (PERT). The innovations include formulations with optimized enzyme ratios, enteric-coated tablets for improved delivery, and microencapsulation technologies to protect enzymes from degradation. These advancements are expected to drive the market growth. |
| Exploration of Novel Therapies | The ongoing research efforts are focused on exploring novel therapeutic approaches beyond traditional enzyme replacement, including enzyme enhancers, pancreatic duct clearance agents, and targeted therapies addressing underlying disease mechanisms. |
| Personalized Medicine Approach | The increasing use of genetic testing helps identify specific mutations (e.g., CFTR mutations in cystic fibrosis-related EPI) that influence treatment responses. This allows for personalized treatment plans tailored to individual genetic profiles, optimizing therapy effectiveness and patient outcomes. This is expected to drive market growth. |
Exocrine Pancreatic Insufficiency Treatment Market Segmentation
Market Breakup by Treatment
- Pancreatic Enzyme Replacement Therapy (PERT)
- Nutritional Therapy (Dietary Supplements)
- Others
Market Breakup by Indication
- Abdominal Pain
- Constipation
- Diarrhea
- Fatty Stools
- Weight Loss
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centers
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Exocrine Pancreatic Insufficiency Treatment Market Share
Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth
By treatment, the market is segmented into pancreatic enzyme replacement therapy (PERT), nutritional therapy (dietary supplements) and others. The pancreatic enzyme replacement therapy (PERT) segment is expected to dominate the market because it is the most recommended treatment. It helps in managing EPI symptoms by replacing the deficient pancreatic enzymes (lipase, protease, amylase) required for proper digestion of fats, proteins, and carbohydrates.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Exocrine Pancreatic Insufficiency Treatment Market Analysis by Region
Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies, is estimated to hold a high market value. The robust research and development activities in pharmaceutical and biotechnology sectors, leading to continuous advancements in pancreatic enzyme replacement therapy (PERT) formulations, driving the regional demand.
Germany holds a high exocrine pancreatic insufficiency treatment market value as the region boasts a well-developed healthcare system with robust diagnostic capabilities and access to specialized care, facilitating early detection and management of EPI.
Additionally, Japan is expected to witness substantial market growth as the region has made significant progress in raising awareness among healthcare providers about gastrointestinal disorders, including EPI. This has led to improved diagnosis and management of the condition and thus driving the market demand.
Leading Players in the Exocrine Pancreatic Insufficiency Treatment Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, fundings and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AbbVie Inc.
AbbVie Inc., a prominent pharmaceutical company, has been involved in the treatment of exocrine pancreatic insufficiency (EPI) through its development and marketing of pancreatic enzyme replacement therapy (PERT) products.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc., as a global pharmaceutical company focuses on several therapeutic areas such as pharmaceuticals, generics, eye care, and oncology, among others, including EPI.
Other key players in the market include Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc., Cilian AG, Chiesi Farmaceutici S.p.A., Anthera Pharmaceuticals, Inc., and Aptalis Pharma Inc. among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Exocrine Pancreatic Insufficiency Treatment Market Report
- What was the exocrine pancreatic insufficiency treatment market value in 2023?
- What is the exocrine pancreatic insufficiency treatment market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment?
- What is market segmentation based on indication?
- What is market segmentation based on end user?
- What are the major factors aiding the exocrine pancreatic insufficiency treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the growing cases of chronic pancreatis affect the market landscape?
- How does the clinical trials impact the market size?
- Who are the key players involved in the exocrine pancreatic insufficiency treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Exocrine Pancreatic Insufficiency Treatment Market Overview – 8 Major Markets
3.1 Exocrine Pancreatic Insufficiency Treatment Market Historical Value (2017-2023)
3.2 Exocrine Pancreatic Insufficiency Treatment Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Exocrine Pancreatic Insufficiency Treatment Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Exocrine Pancreatic Insufficiency Treatment Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality, by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Exocrine Pancreatic Insufficiency Treatment Market Landscape – 8 Major Markets
8.1 Exocrine Pancreatic Insufficiency Treatment: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Exocrine Pancreatic Insufficiency Treatment: Product Landscape
8.2.1 Analysis by Treatment
8.2.2 Analysis by Indication
9 Exocrine Pancreatic Insufficiency Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Exocrine Pancreatic Insufficiency Treatment Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Environmental
11.3.3 Social
11.3.4 Technological
11.3.5 Ethical
11.3.6 Legal
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Exocrine Pancreatic Insufficiency Treatment Market Segmentation (2017-2032) - 8 Major Markets
12.1 Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Treatment
12.1.1 Market Overview
12.1.2 Pancreatic Enzyme Replacement Therapy (PERT)
12.1.3 Nutritional Therapy (Dietary Supplements)
12.1.4 Others
12.2 Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Indication
12.2.1 Market Overview
12.2.2 Abdominal Pain
12.2.3 Constipation
12.2.4 Diarrhea
12.2.5 Fatty Stools
12.2.6 Weight Loss
12.2.7 Others
12.3 Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by End User
12.3.1 Market Overview
12.3.2 Hospitals
12.3.3 Homecare
12.3.4 Specialty Centers
12.3.5 Others
12.4 Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Exocrine Pancreatic Insufficiency Treatment Market (2017-2032)
13.1 United States Exocrine Pancreatic Insufficiency Treatment Market Historical Value (2017-2023)
13.2 United States Exocrine Pancreatic Insufficiency Treatment Market Forecast Value (2024-2032)
13.3 United States Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Treatment
13.3.1 Market Overview
13.3.2 Pancreatic Enzyme Replacement Therapy (PERT)
13.3.3 Nutritional Therapy (Dietary Supplements)
13.3.4 Others
13.4 United States Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Indication
13.4.1 Market Overview
13.4.2 Abdominal Pain
13.4.3 Constipation
13.4.4 Diarrhea
13.4.5 Fatty Stools
13.4.6 Weight Loss
13.4.7 Others
14 EU-4 and United Kingdom Exocrine Pancreatic Insufficiency Treatment Market (2017-2032)
14.1 EU-4 and United Kingdom Exocrine Pancreatic Insufficiency Treatment Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Exocrine Pancreatic Insufficiency Treatment Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Treatment
14.3.1 Market Overview
14.3.2 Pancreatic Enzyme Replacement Therapy (PERT)
14.3.3 Nutritional Therapy (Dietary Supplements)
14.3.4 Others
14.4 EU-4 and United Kingdom Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Indication
14.4.1 Market Overview
14.4.2 Abdominal Pain
14.4.3 Constipation
14.4.4 Diarrhea
14.4.5 Fatty Stools
14.4.6 Weight Loss
14.4.7 Others
15 Japan Exocrine Pancreatic Insufficiency Treatment Market
15.1 Japan Exocrine Pancreatic Insufficiency Treatment Market Historical Value (2017-2023)
15.2 Japan Exocrine Pancreatic Insufficiency Treatment Market Forecast Value (2024-2032)
15.3 Japan Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Treatment
15.3.1 Market Overview
15.3.2 Pancreatic Enzyme Replacement Therapy (PERT)
15.3.3 Nutritional Therapy (Dietary Supplements)
15.3.4 Others
15.4 Japan Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Indication
15.4.1 Market Overview
15.4.2 Abdominal Pain
15.4.3 Constipation
15.4.4 Diarrhea
15.4.5 Fatty Stools
15.4.6 Weight Loss
15.4.7 Others
16 India Exocrine Pancreatic Insufficiency Treatment Market
16.1 India Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) Historical Value (2017-2023)
16.2 India Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) Forecast Value (2024-2032)
16.3 India Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Treatment
16.3.1 Market Overview
16.3.2 Pancreatic Enzyme Replacement Therapy (PERT)
16.3.3 Nutritional Therapy (Dietary Supplements)
16.3.4 Others
16.4 India Exocrine Pancreatic Insufficiency Treatment Market (2017-2032) by Indication
16.4.1 Market Overview
16.4.2 Abdominal Pain
16.4.3 Constipation
16.4.4 Diarrhea
16.4.5 Fatty Stools
16.4.6 Weight Loss
16.4.7 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership and Collaborations
22.3 Analysis by Joint Ventures
22.4 Analysis by Leading Players
22.5 Analysis by Region
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 AbbVie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Johnson & Johnson Services, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Chiesi Farmaceutici S.p.A.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Nordmark Arzneimittel GmbH and Co. KG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Digestive Care, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Cilian AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Anthera Pharmaceuticals, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Aptalis Pharma Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
24 Exocrine Pancreatic Insufficiency Treatment Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER